China’s insulin plans will hit 2022 revenues, says Novo NordiskNovo Nordisk has said that the introduction of value-based procurement (VBP) for insulin products by the Chinese government Share XChina’s insulin plans will hit 2022 revenues, says Novo Nordiskhttps://pharmaphorum.com/news/chinas-insulin-plans-will-hit-2022-revenues-says-novo-nordisk/
Novo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeover dealDanish drugmaker Novo Nordisk must like what it has seen in its two-year-old alliance with gene-silencing specialist Dicerna Share XNovo Nordisk snaps up RNAi partner Dicerna in $3.3bn takeover dealhttps://pharmaphorum.com/news/novo-nordisk-snaps-up-rnai-partner-dicerna-in-3-3bn-takeover-deal/
Novo Nordisk on seeking partnerships to expand its portfolioIts vast experience in diabetes and the amount of data collected has propelled Novo Nordisk into exploring new Share XNovo Nordisk on seeking partnerships to expand its portfoliohttps://pharmaphorum.com/r-d/novo-nordisk-seeking-partnerships-diabetes/
Novo Nordisk nears EU approval of obesity drug WegovyDanish drugmaker Novo Nordisk is hoping to launch its once-weekly injectable treatment for obesity, Wegovy, in the EU Share XNovo Nordisk nears EU approval of obesity drug Wegovyhttps://pharmaphorum.com/news/novo-nordisk-nears-eu-approval-of-obesity-drug-wegovy/
Lilly grabs glucose-sensing insulin tech, buying Protomer in $1bn dealEli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must Share XLilly grabs glucose-sensing insulin tech, buying Protomer in $1bn dealhttps://pharmaphorum.com/news/lilly-grabs-glucose-sensing-insulin-tech-buying-protomer-in-1bn-deal/
Novo Nordisk bulks up in rare diseases with $1.2bn Prothena dealDiabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition Share XNovo Nordisk bulks up in rare diseases with $1.2bn Prothena dealhttps://pharmaphorum.com/news/novo-nordisk-bulks-up-in-rare-diseases-with-1-2bn-prothena-deal/
Experts discuss the field force’s customer-centric futureThe ways in which HCPs prefer to engage with pharma has been changing for quite some time, and Share XExperts discuss the field force’s customer-centric futurehttps://pharmaphorum.com/sales-marketing/experts-discuss-the-field-forces-customer-centric-future/
FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s WegovyNovo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which Share XFDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovyhttps://pharmaphorum.com/news/fda-ends-obesity-drug-drought/
Novo Nordisk crowns cell therapy pipeline with $598m Heartseed dealNovo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed Share XNovo Nordisk crowns cell therapy pipeline with $598m Heartseed dealhttps://pharmaphorum.com/news/novo-nordisk-crowns-cell-therapy-pipeline-with-598m-heartseed-deal/
